SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-027784
Filing Date
2021-11-10
Accepted
2021-11-10 10:40:04
Documents
14
Period of Report
2021-11-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 60511
2 ex99-1.htm EX-99.1 14869
  Complete submission text file 0001493152-21-027784.txt   302399

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ensc-20211110.xsd EX-101.SCH 3748
4 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ensc-20211110_def.xml EX-101.DEF 26616
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ensc-20211110_lab.xml EX-101.LAB 36643
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ensc-20211110_pre.xml EX-101.PRE 25234
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5523
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 211395181
SIC: 2834 Pharmaceutical Preparations